姓名：洪明

性別：男

職稱：副研究員

學(xué)術(shù)兼職：（高校服務(wù)國家重大戰(zhàn)略出版工程“抗腫瘤中藥現(xiàn)代研究與臨床應(yīng)用”編委）

地址：中山市人民醫(yī)院先進(jìn)診斷與先進(jìn)治療臨床研究中心

E-mail：hongming530[at]126[dot]com

個(gè)人簡歷：

2004.09~2008.07 江西中醫(yī)藥大學(xué)生物工程系學(xué)習(xí)，獲生物工程學(xué)士學(xué)位

2008.07~2011.07軍事醫(yī)學(xué)科學(xué)院基礎(chǔ)醫(yī)學(xué)研究所學(xué)習(xí)獲遺傳學(xué)碩士學(xué)位

2011.07~2011.12 華大基因分子診斷高級(jí)專員

2013.01~2013.04 香港大學(xué)解剖系研究助理2013.05~2017.09香港大學(xué)醫(yī)學(xué)部學(xué)習(xí)獲中藥藥理學(xué)博士學(xué)位

2017.12~2020.12廣州中醫(yī)藥大學(xué)科技創(chuàng)新中心副研究員碩士生導(dǎo)師

2018.06~2018.07  美國堪薩斯大學(xué)藥理與毒理系訪問學(xué)者

2021.01~2022.03  廣州大學(xué)中山市人民醫(yī)院生命醫(yī)學(xué)聯(lián)合研究院獨(dú)立PI   副研究員

2022.04至今 中山市人民醫(yī)院先進(jìn)診斷與先進(jìn)治療臨床研究中心 副研究員

主要研究方向（課題）：

　　主要從事中藥抗腫瘤活性及其分子機(jī)制的研究工作。綜合利用網(wǎng)絡(luò)藥理學(xué)，分子對(duì)接技術(shù)以及體內(nèi)，體外試驗(yàn)預(yù)測中藥的抗腫瘤活性成分及其分子機(jī)制。主要研究方向天然藥物抗腫瘤分子機(jī)制的研究。

代表性論文、論著和成果：

[1] Ming Hong , Tin Lan, Qiuxia Li, BinfeiLi Yong Yuan, Feng Xu , Weijia Wang. A comprehensive perspective on theinteraction between gut microbiota and COVID-19 vaccines. Gut Microbes. 2023Jan-Dec;15(1):2233146. (IF：12.2)

[2] Li SY, Wang WJ, Li QY, Yang PH, Li XL,Yan Y, Yuan Y, Feng YB, Hong M*. Using omics approaches to dissect thetherapeutic effects of Chinese herbal medicines on gastrointestinal cancers.Front Pharmacol. 2022 Sep 23;13:884822. doi: 10.3389/fphar.2022.884822.eCollection 2022.

[3] Ming Hong*, Mohammed M.Almutairi，Siying Li, Jinke Li* Wogonin inhibits cell cycle progression byactivating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.Phytomedicine. 2020 Jan 18;68:153174.

[4] Bingyu SUN, Yongqiang LIU, Danhua HE,Jinke LI, Jiawei WANG, Wulin WEN*, Ming HONG*, 2021. Traditional Chinesemedicines and their active ingredients sensitizecancer cells to TRAIL-inducedapoptosis. Journal of Zhejiang University-Science B (Biomedicine &Biotechnology), 22(3):190-203(IF:3.1 JCR 2區(qū)) (IF：6.543 JCR 1區(qū))

[5] Yi Luo, Yu Feng, Lei Song, Gan-Qing He,Sha Li, Sha-Sha Bai, Yu-Jie Huang, Si-Ying Li, Mohammed M. Almutairi, Hong-LianShi, Qi Wang, Ming Hong*. A network pharmacology-based study on theanti-hepatoma effect of Radix Salviae Miltiorrhizae. Chinese Medicine. 2019; 14

[6] Lei Song, Yi Luo, Yue-xin Wang,Mohammed M.Almutairi, Feng-hua Pan, Rong-wei Li, Qiang yong Liu, Qi Wang*, MingHong*. Exploring the Active Mechanism of Berberine Against HepatocellularCarcinoma by Systematic Pharmacology and Experimental Validation.Molecular  Medicine Reports. 2019 Volume20 Issue 5 https://doi.org/10.3892/mmr.2019.10698  

[7] Hong M#, Shi H#, Wang N, Tan HY, WangQ*, Feng Y* Dual Effects of Chinese Herbal Medicines on Angiogenesis in Cancerand Ischemic Stroke Treatments: Role of HIF-1 Network. Front Pharmacol. 2019Jun 26;10:696. doi: 10.3389/fphar.2019.00696. eCollection 2019.

[8] Ming Hong*#, Zhe Cai#, Lei Song,Yongqiang Liu, Qi Wang* and Xiangfei Feng*. Gynostemma pentaphyllum attenuatesthe progression of Non-alcoholic fatty liver disease in Mice: a biomedicalinvestigation integrated with in silico assay. Evidence-Based Complementary andAlternative Medicine. Volume 2018, Article ID 8384631, 13 pages

[9] Ming Hong*#, Honghui Cheng#, Lei Song,Wencai Wang, Qi Wang, Donggang Xu and Weiwei Xing*. Wogonin Suppresses theActivity of Matrix Metalloproteinase-9 and Inhibits Migration and Invasion inHuman Hepatocellular Carcinoma. Molecules. 2018, 23(2), 384;doi:10.3390/molecules23020384.

[10] Ming Hong#, Yongsheng Zhang#, Sha Li,Hor Yue Tan, Ning Wang, Shuzhen Mu, Xiaojiang Hao，Yibin Feng*. A Network Pharmacology-Based Study on theHepatoprotective Effect of Fructus Schisandrae. Molecules. 2017, 22(10), 1617;doi:10.3390/molecules22101617.

[11] Hong M, Li S, Tan HY, Cheung F, WangN, Huang J, Feng Y*. A Network-Based Pharmacology Study of the Herb-InducedLiver Injury Potential of Traditional Hepatoprotective Chinese HerbalMedicines. Molecules. 2017, 22(4), 632; doi:10.3390/molecules22040632.

[12] Hong M, Li S, Wang N, Tan HY, CheungF, Feng Y*. A Biomedical Investigation on the Hepatoprotective Effect of RadixSalviae Miltiorrhizae and Network pharmacology-based Prediction of the Activecompunds and Molecular Targets. Int. J. Mol. Sci. 2017, 18(3), 620;doi:10.3390/ijms18030620.

[13] Hong M, Tan HY, Li S, Cheung F, Wang NNagamatsu T, Feng Y*. Cancer Stem Cells: The Potential Targets of ChineseMedicines and Their Active Compounds. Int J Mol Sci. 2016. 17(6).  

[14] Hong M, Wang N, Tan HY, Tsao SW, FengY*. MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy.Cancers (Basel). 2015. 7(3): p. 1643-57.

[15] Ming Hong, Sha Li, Hor Yue Tan, NingWang, Sai-Wah Tsao and Yibin Feng. Current Status of Herbal Medicines inChronic Liver Disease Therapy: The Biological Effects, Molecular Targets andFuture Prospects. Int. J. Mol. Sci. 2015, 16(12), 28705-28745.

[16] Cai Z#, Hong M#, Xu L, Yang K, Li C,Sun T, Feng Y, Zeng H, Lu WW, Chiu KY. Prevent action of magnoflorine withhyaluronic acid gel from cartilage degeneration in anterior cruciate ligamenttransection induced osteoarthritis. Biomed Pharmacother. 2020 Jun;126:109733.

[17] Luo Y, Song L, Wang X, Huang Y, Liu Y,Wang Q, Hong M* and Yuan Z*. Uncovering the Mechanisms of Cryptotanshinone as aTherapeutic Agent Against Hepatocellular Carcinoma. Front. Pharmacol. 11:1264.

[18] Hong M, Zha L, Fu W, Zou M, Li W, XuD. A modified visual loop-mediated isothermal amplification method fordiagnosis and differentiation of main pathogens from Mycobacterium tuberculosiscomplex. World J Microbiol Biotechnol. 2012 Feb;28(2):523-31.

1. 國家自然科學(xué)基金（24萬），項(xiàng)目編號(hào)：820041612021.1-2023.12 負(fù)責(zé)人：洪明

2.廣東省基礎(chǔ)與應(yīng)用基礎(chǔ)研究基金項(xiàng)目（10萬），項(xiàng)目編號(hào): 2019A15151101672020.1-2021.12 負(fù)責(zé)人：洪明

3. 2022年度中山市第三批社會(huì)公益與基礎(chǔ)研究項(xiàng)目（重點(diǎn)項(xiàng)目）（15萬）項(xiàng)目編號(hào)：20428084378410 2023.1-2024.12負(fù)責(zé)人：洪明

獲得榮譽(yù)：

　　香港大學(xué)醫(yī)學(xué)部2017屆優(yōu)秀博士論文